AAV Vectors Delivering TCAP cDNA for LGMDR7 Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autosomal recessive limb-girdle muscular dystrophy type R7 (LGMDR7) and associated cardiomyopathies lack effective therapeutic options to halt or slow disease progression.

Innovation Solution

The use of gene therapy vectors, specifically adeno-associated virus (AAV) vectors, to deliver a TCAP cDNA or wild-type TCAP cDNA to subjects, promoting the expression of functional TCAP protein in human striated muscles.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If gene therapy vectors (AAV) are used to deliver TCAP cDNA, then robust and long-term expression of functional TCAP protein is achieved, but the complexity of the treatment system increases

Engineering Contradiction:

Improvelong-term expression of TCAP proteinVSAvoidgene therapy vector system

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses AAV vectors as intermediary carriers to deliver the TCAP cDNA sequence into muscle cells. The vector acts as a mediator that transports the genetic material without integrating into the host genome, providing stable long-term expression while maintaining relative simplicity in the delivery mechanism.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs a simplified copy of the TCAP gene (cDNA sequence) rather than the complete genomic sequence. This copying approach removes unnecessary regulatory elements and introns, resulting in a streamlined genetic payload that expresses functional protein reliably without the complexity of native gene structure.

Inventive Principle:

Principle #26Copying

2Reliability

If TCAP cDNA is delivered to muscle cells, then functional TCAP protein is expressed, but the difficulty of delivering genetic material to target tissues increases

Engineering Contradiction:

Improvefunctional protein expressionVSAvoiddelivery of genetic material

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The AAV vector serves as a pre-fabricated intermediary vehicle that is easily manufactured and can efficiently cross the blood-brain barrier and deliver payload to muscle tissues. This mediator approach simplifies the delivery process compared to direct nucleic acid administration.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent optimizes parameters of the AAV vector such as serotype selection, capsid structure, and genome packaging to enhance delivery efficiency. By changing these parameters, the system achieves reliable transduction of muscle cells while maintaining ease of manufacturing through standardized production protocols.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250152740A1Materials and methods for the treatment of limb girdle muscular dystrophy

Publication Date: 2025.05.15 RES INST AT NATIONWIDE CHILDRENS HOSPITAL

AI summary

Provided are gene therapy vectors, such as adeno-associated virus (AAV), designed for treatment of mutations in the TCAP gene. Such mutations are also known as telethoninopathies and are associated with such disorders as autosomal recessive limb girdle muscular dystrophy type 2G (LGMD2G), autosomal dominant dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM) or idiopathic cardiomyopathy (ICM). The disclosed gene therapy vectors provide a TCAP cDNA to a subject in need which results in expression of a wild type or functional TCAP or telethonin protein.